Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status

Sacituzumab govitecan is in clinical development for the treatment of adult patients with previously untreated locally advanced or metastatic triple negative breast cancer (TNBC) with PD-L1- status. TNBC is a rare form of breast cancer where the tumour cells do not have hormone response receptors such as oestrogen or progesterone. PD-L1 is a protein involved in the activation of an immune response. Locally advanced breast cancer is cancer that has progressed locally but has not yet spread outside the breast and local lymph nodes, whereas metastatic breast cancer is cancer that has spread to other areas in the body. Symptoms of TNBC can include a new lump or thickening in the breast or armpit. Established risk factors of breast cancer include age, early onset of menstruation, late menopause, older age at first completed pregnancy, and a family history. Treatment options for TNBC are limited and are often associated with short-lived benefits and higher susceptibility to treatment resistance in the future.